Effect of tamsulosin on ureteric stent related morbidity: a double-blind randomized placebo-controlled study

Ripudaman Singh, Gurpreet Singh Bhangu, Darpan Bansal, Anuj Rattan


Background: Post ureteral stenting, symptoms occurs of lower urinary tract which impact quality of life in around 80% of patients, urgency, frequency, dysuria, suprapubic pain, hematuria. α1-Adrenoceptors are found in highest density in the distal ureter. α1-Adrenoceptor antagonists dilates the lumen of the ureter and reduces the spasms by decreasing the peristaltic frequency and inhibiting basal tone of the ureter, leading to improvement in stent-related symptoms. This study was conducted to study effect of tamsulosin, a selective α1A- and α1D-adrenoceptor antagonist in relieving ureteric stent related symptoms

Methods: A randomized double blinded placebo-controlled study conducted from February 2019 to August 2020 in Department of Surgery SGRD University, Amritsar. We enrolled 60 patients with each group of 30 patients (Group A placebo and Group B Tamsilosin 0.4 mg). IPSS (irritative and obstructive), quality of life (QoL) and visual analog scale VAS) pain score were calculated based on post-operative day one versus at Stent removal day (Post-operative day 21) at 3 weeks observations. analysis was done using Statistical package for social sciences (SPSS) version 23.0. Student ‘t’test (unpaired) and Chi-square test.

Results: IPSS, QoL and VAS showed improvement with significant relieve of symptoms in patients on tamsulosin compared to placebo at time of stent removal.

Conclusions: The study concluded that administration of tamsulosin a selective α1-blocker is useful in decreasing lower urinary tract symptoms in patients undergoing ureteral stenting.


Ureteral stent, Tamsulosin, Stent syndrome

Full Text:



Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35:1301-20.

Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol. 1967;97:840-4.

Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in ureteral stent design and materials. Curr Urol Rep. 2018;19:35.

Dyer RB, Chen MY, Zagoria RJ. Complications of ureteral stent placement. Radiographics. 2012;22(5):1005-22.

Hao P, Li W, Song C, Yan J, Song B, Li L. Clinical evaluation of double pigtail stent in patients with upper urinary tract diseases: Report of 2685 cases. J Endo Urol. 2008;22:65-70.

Nitti V, Brucker BM. Urodynamic and videourodynamic evaluation of voiding dysfunction. Campbell-Walsh Urology. 11th ed. Philadelphia, PA: Elsevier. 2016;1718-42.

Deliveliotis C, Chrisofos M, Gougousis E. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urol. 2006;67:35-9.

Jeong H, Hawk C, Lee SE. Ureteric stenting after ureteroscopy for ureteric stones: a prospective randomized study assessing symptoms and complications. BJU Int. 2004;93:1032-5.

Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: A prospectively randomized study. Urol Res. 2009;37:147-52.

Singh I, Tripathy S, Agrawal V. Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study. Int Urol Nephrol. 2014;46:2279-83.

Lim KT, Kim YT, Lee TY, Park SY. Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts. Korean journal of urology.

Navanimitkul N, Lojanapiwat B. Efficacy of Tamsulosin 0.4 mg/day in Relieving Double-J Stent-Related Symptoms: A Randomized Controlled Study. J Int Med Res. 2010;1436-41.